Dupixent's COPD data breathe new life into Sanofi stock

22 May 2023

Positive Phase III results for Sanofi’s (Euronext: SAN) trailblazing biologic Dupixent (dupilumab) could open up a significant opportunity in a new treatment setting.

Long used as a treatment for atopic dermatitis (AD), Sanofi and partner Regeneron Pharmaceuticals (Nasdaq: REGN) have invested heavily in broadening Dupixent’s use in areas where type 2 inflammation is a driving factor.

Other than AD, the product is used to treat asthma, chronic rhinosinusitis, prurigo nodularis and eosinophilic esophagitis, bringing in 2.3 billion euros ($2.5 billion) in the first quarter, an increase of 40%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK